Hardman Johnston Global Advisors, an investment management firm, issued its Q3 2026 investor letter for the “Hardman Johnston International Equity Developed Markets Strategy”. The letter can be downloaded here. The strategy faced a challenging third quarter, underperforming its benchmark with a return of -5.51% versus +0.81% for the MSCI EAFE Net Index. Consumer Staples and […]

JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an "overweight" rating in a research note on Monday.

The Nov. 11 event starts at 8:30 a.m. ET, with presentations expected to end at 12:30 p.m.; a live webcast and materials will be online.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Weltruza es el segundo producto de Teva aprobado en EE. UU. elaborado en asociación con la empresa francesa de biotecnología Medincell. Utiliza tecnología inyectable de acción prolongada, diseñada para liberar medicamentos durante un período prolongado.

'Those still taking Teva's money can no longer shelter behind the excuse that nothing can be done,' an NHS doctor told the Guardian, urging other medical bodies to follow suit